Alden A. Moccia

2.9k total citations
39 papers, 871 citations indexed

About

Alden A. Moccia is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Alden A. Moccia has authored 39 papers receiving a total of 871 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pathology and Forensic Medicine, 20 papers in Oncology and 13 papers in Neurology. Recurrent topics in Alden A. Moccia's work include Lymphoma Diagnosis and Treatment (37 papers), Viral-associated cancers and disorders (16 papers) and CNS Lymphoma Diagnosis and Treatment (13 papers). Alden A. Moccia is often cited by papers focused on Lymphoma Diagnosis and Treatment (37 papers), Viral-associated cancers and disorders (16 papers) and CNS Lymphoma Diagnosis and Treatment (13 papers). Alden A. Moccia collaborates with scholars based in Switzerland, Canada and Italy. Alden A. Moccia's co-authors include Joseph M. Connors, Laurie H. Sehn, Kerry J. Savage, Randy D. Gascoyne, Richard Klasa, Paul Hoskins, Tamara Shenkier, Emanuele Zucca, Graham W. Slack and Anastasios Stathis and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Alden A. Moccia

38 papers receiving 858 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alden A. Moccia Switzerland 15 774 475 259 207 146 39 871
Eve Gallop‐Evans United Kingdom 14 610 0.8× 375 0.8× 266 1.0× 255 1.2× 84 0.6× 27 892
Viola Poeschel Germany 13 707 0.9× 459 1.0× 236 0.9× 269 1.3× 105 0.7× 39 872
Allison Crosby‐Thompson United States 6 675 0.9× 393 0.8× 239 0.9× 181 0.9× 153 1.0× 11 891
Niels Murawski Germany 16 716 0.9× 483 1.0× 340 1.3× 298 1.4× 94 0.6× 39 964
Alina S. Gerrie Canada 18 800 1.0× 465 1.0× 260 1.0× 422 2.0× 157 1.1× 110 1.1k
F. Morschhauser France 13 693 0.9× 449 0.9× 166 0.6× 182 0.9× 123 0.8× 27 944
Lisa Lowry United Kingdom 9 634 0.8× 482 1.0× 229 0.9× 162 0.8× 146 1.0× 19 763
Lluı́s Colomo Spain 15 622 0.8× 516 1.1× 123 0.5× 297 1.4× 245 1.7× 35 1.0k
Benedetta Puccini Italy 15 640 0.8× 271 0.6× 257 1.0× 131 0.6× 182 1.2× 56 804
Charles Foussard France 12 885 1.1× 601 1.3× 195 0.8× 356 1.7× 59 0.4× 22 1.0k

Countries citing papers authored by Alden A. Moccia

Since Specialization
Citations

This map shows the geographic impact of Alden A. Moccia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alden A. Moccia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alden A. Moccia more than expected).

Fields of papers citing papers by Alden A. Moccia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alden A. Moccia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alden A. Moccia. The network helps show where Alden A. Moccia may publish in the future.

Co-authorship network of co-authors of Alden A. Moccia

This figure shows the co-authorship network connecting the top 25 collaborators of Alden A. Moccia. A scholar is included among the top collaborators of Alden A. Moccia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alden A. Moccia. Alden A. Moccia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eichenauer, Dennis A., Christian Baues, Carsten Kobe, et al.. (2023). Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies. Blood. 142(6). 553–560. 6 indexed citations
2.
Moccia, Alden A., Christian Taverna, Sämi Schär, et al.. (2020). Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. Blood Advances. 4(23). 5951–5957. 17 indexed citations
3.
Ceriani, Luca, Giuseppe Gritti, Luciano Cascione, et al.. (2020). SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. Blood Advances. 4(6). 1082–1092. 57 indexed citations
4.
5.
Freeman, Ciara L., Robert Kridel, Alden A. Moccia, et al.. (2019). Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 134(9). 761–764. 84 indexed citations
6.
Voltin, Conrad‐Amadeus, Helen Goergen, Christian Baues, et al.. (2018). Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18. Annals of Oncology. 29(9). 1926–1931. 33 indexed citations
7.
Moccia, Alden A. & Catherine Thiéblemont. (2018). Curing diffuse large B-cell lymphomas in elderly patients. European Journal of Internal Medicine. 58. 14–21. 11 indexed citations
8.
Mettler, Jasmin, Horst Müller, Conrad‐Amadeus Voltin, et al.. (2018). Metabolic Tumor Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma. Journal of Nuclear Medicine. 60(2). 207–211. 59 indexed citations
9.
Bröckelmann, Paul J., Helen Goergen, Bastian von Tresckow, et al.. (2017). Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials. Journal of Clinical Oncology. 35(13). 1444–1450. 27 indexed citations
10.
Domenighetti, G, et al.. (2016). Observational case-control study of non-invasive ventilation in patients with ARDS. Monaldi Archives for Chest Disease. 69(1). 5–10.
11.
Moccia, Alden A., Felicitas Hitz, Paul Hoskins, et al.. (2016). Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. Leukemia & lymphoma. 58(2). 324–332. 32 indexed citations
12.
Conconi, Annarita, Silvia Franceschetti, Kathrin Aprile von Hohenstaufen, et al.. (2015). Histologic transformation in marginal zone lymphomas. Annals of Oncology. 26(11). 2329–2335. 77 indexed citations
13.
Hitz, Felicitas, Joseph M. Connors, Randy D. Gascoyne, et al.. (2015). Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment. Annals of Hematology. 94(11). 1839–1843. 54 indexed citations
14.
Steffanoni, Sara, Michele Ghielmini, & Alden A. Moccia. (2015). Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options. Expert Review of Anticancer Therapy. 15(11). 1337–1349. 4 indexed citations
15.
Al-Tourah, Abdulwahab J., Laurie H. Sehn, Alden A. Moccia, Randy D. Gascoyne, & Joseph M. Connors. (2012). Transformation of follicular lymphoma in the era of immunochemotherapy: A population-based study from British Columbia.. Journal of Clinical Oncology. 30(15_suppl). 8049–8049. 8 indexed citations
16.
Kridel, Robert, King Tan, Abdulwahab J. Al-Tourah, et al.. (2012). Tumor-Associated Macrophages Predict Outcome in Follicular Lymphoma. Blood. 120(21). 682–682. 1 indexed citations
17.
18.
Hitz, Felicitas, Joseph M. Connors, Randy D. Gascoyne, et al.. (2010). Outcome of Patients with Chemotherapy Refractory and Early Progressive Diffuse Large B Cell Lymphoma After R-CHOP Treatment. Blood. 116(21). 1751–1751. 7 indexed citations
19.
20.
Moccia, Alden A. & Michele Ghielmini. (2008). Monoclonal Antibodies for the Treatment of Hematologic Malignancies: Schedule and Maintenance Therapy. Seminars in Hematology. 45(2). 75–84. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eve Gallop‐Evans Breakdown of academic impact, for papers by Viola Poeschel Breakdown of academic impact, for papers by Allison Crosby‐Thompson Breakdown of academic impact, for papers by Niels Murawski Breakdown of academic impact, for papers by Alina S. Gerrie Breakdown of academic impact, for papers by F. Morschhauser Breakdown of academic impact, for papers by Lisa Lowry Breakdown of academic impact, for papers by Lluı́s Colomo Breakdown of academic impact, for papers by Benedetta Puccini Breakdown of academic impact, for papers by Charles Foussard
Rankless by CCL
2026